Triggering regeneration and tackling apoptosis: a combinatorial approach to treating congenital muscular dystrophy type 1 A

Quercetin Treatment Ameliorates Inflammation and Fibrosis in Mice with Nonalcoholic Steatohepatitis1–3

(2012) Eder Marcolin et al.   JOURNAL OF NUTRITION

Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy2J/dy2J Mouse

(2011) Moran Elbaz et al.   ANNALS OF NEUROLOGY

Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice

(2011) Sarina Meinen et al.   EMBO Molecular Medicine

Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A

(2011) A. Kumar et al.   HUMAN MOLECULAR GENETICS

Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin- 2-deficient mouse model of congenital muscular dystrophy

(2011) S. Homma et al.   HUMAN MOLECULAR GENETICS

Autophagy is increased in laminin α2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A

(2011) Virginie Carmignac et al.   HUMAN MOLECULAR GENETICS

Open-Label Trial of Recombinant Human Insulin-like Growth Factor 1/Recombinant Human Insulin-like Growth Factor Binding Protein 3 in Myotonic Dystrophy Type 1

(2010) Chad R. Heatwole et al.   ARCHIVES OF NEUROLOGY

NF-κB Signaling in the Aging Process

(2009) Antero Salminen et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Pathology is alleviated by doxycycline in a laminin-α2-null model of congenital muscular dystrophy

(2008) Mahasweta Girgenrath et al.   ANNALS OF NEUROLOGY

Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging

(2007) Antero Salminen et al.   AGEING RESEARCH REVIEWS